Is increasing the dose of entecavir effective in partial virological responders?
| dc.contributor.author | Ertürk, Ayşe | |
| dc.contributor.author | Akdoğan, Remzi Adnan | |
| dc.contributor.author | Parlak, Emine | |
| dc.contributor.author | Cüre, Erkan | |
| dc.contributor.author | Cüre, Medine Cumhur | |
| dc.contributor.author | Öztürk, Çınar | |
| dc.date.accessioned | 2020-12-19T20:13:17Z | |
| dc.date.available | 2020-12-19T20:13:17Z | |
| dc.date.issued | 2014 | |
| dc.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | |
| dc.description | PubMed: 24936126 | |
| dc.description.abstract | Objective: To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year. Methods: Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA. Results: Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years. Conclusion: Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication. © 2014 Erturk et al. | |
| dc.identifier.citation | Erturk, A., Akdogan, R. A., Parlak, E., Cure, E., Cumhur Cure, M., & Ozturk, C. (2014). Is increasing the dose of Entecavir effective in partial virological responders?. Drug design, development and therapy, 8, 621–625. https://doi.org/10.2147/DDDT.S61045 | |
| dc.identifier.doi | 10.2147/DDDT.S61045 | |
| dc.identifier.endpage | 625 | |
| dc.identifier.issn | 1177-8881 | |
| dc.identifier.pmid | 24936126 | |
| dc.identifier.scopus | 2-s2.0-84901772505 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 621 | |
| dc.identifier.uri | https://doi.org/10.2147/DDDT.S61045 | |
| dc.identifier.uri | https://hdl.handle.net/11436/4002 | |
| dc.identifier.volume | 8 | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Ertürk, Ayşe | |
| dc.institutionauthor | Akdoğan, Remzi Adnan | |
| dc.institutionauthor | Cüre, Erkan | |
| dc.institutionauthor | Cüre, Medine Cumhur | |
| dc.institutionauthor | Öztürk, Çınar | |
| dc.language.iso | en | |
| dc.publisher | Dove Medical Press Ltd. | |
| dc.relation.ispartof | Drug Design, Development and Therapy | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Chronic hepatitis b | |
| dc.subject | Entecavir | |
| dc.subject | Patient monitoring | |
| dc.subject | Treatment | |
| dc.title | Is increasing the dose of entecavir effective in partial virological responders? | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1
Yükleniyor...
- İsim:
- ertürk-2014.pdf
- Boyut:
- 498.31 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin / Full Text











